AngioDynamics Inc. (ANGO) - 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly report on Form 10-Q for AngioDynamics, Inc. for the three and six months ended November 30, 2025. The Company is a medical technology firm focused on cardiovascular disease and cancer treatment, operating through two segments: Med Tech (Auryon, thrombus management, NanoKnife) and Med Device (Core, Venous, Ports, Oncology). As of January 2, 2026, there were 41,217,386 shares of common stock outstanding.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Nov 30, 2025 | 6 Months Ended Nov 30, 2025 |
|---|---|---|
| Net Sales | $79,433 | $155,144 |
| Gross Margin | $44,783 (56.4%) | $86,640 (55.8%) |
| Operating Loss | $(6,125) | $(16,781) |
| Net Loss | $(6,350) | $(17,253) |
| Loss Per Share (Diluted) | $(0.15) | $(0.42) |
| Cash and Cash Equivalents | $41,638 | $41,638 |
| Net Cash Used in Operating Activities | N/A | $(11,253) |
| Long-Term Debt | $0 | $0 |
Note: The Company maintains a $25.0 million secured revolving credit facility with no amounts outstanding as of November 30, 2025.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 9.0% year-over-year (YoY) for the quarter and 10.6% for the six-month period.
- Med Tech: Revenue grew 13.0% (Q) and 19.1% (6M), driven by Auryon, NanoKnife, and thrombus management products.
- Med Device: Revenue grew 6.0% (Q) and 4.2% (6M), driven by Core, Venous, and Ports, partially offset by softness in Oncology.
- Margin Expansion: Gross margin improved by 160 basis points (bps) to 56.4% for the quarter and 120 bps to 55.8% for the six months. Improvements were driven by sales volume, price, product mix, and third-party manufacturing transitions, partially offset by tariffs and inflation.
- Profitability: Net loss narrowed significantly, decreasing by $4.4 million for the quarter and $6.3 million for the six months compared to the prior year periods.
- Operating Expenses: R&D expenses increased due to clinical trial timing. Sales and marketing expenses rose due to compensation and consulting costs. Restructuring and acquisition-related costs decreased by $2.2 million (Q) and $3.8 million (6M) YoY.
Outlook, Risks, and Unusual Items
- Executive Transition: Subsequent to the quarter end, on January 2, 2026, CEO James C. Clemmer notified the Board of his intention to retire, effective November 30, 2026, or upon appointment of a successor. A search committee has been established.
- Restructuring: The Company continues a restructuring plan announced in January 2024 to optimize its manufacturing footprint. Total charges recorded to date are $28.0 million. Remaining estimated costs range from $33.4 million to $38.4 million.
- Legal Proceedings:
- C.R. Bard Litigation: A settlement agreement with BD (parent of Bard) involves a $7.0 million lump sum payment and annual minimum payments of $2.5 million. A Federal Circuit ruling in December 2025 affirmed patent invalidity in favor of AngioDynamics, eliminating contingent payments beyond the minimums.
- Product Liability: The Company is defending approximately 268 product liability claims related to port products.
- Liquidity: Management believes current cash ($41.6 million) and the revolving credit facility provide sufficient liquidity for the next 12 months. No share repurchases were made in the current six-month period; $13.3 million remains available under the existing program.
- Risks: Key risks include supply chain challenges, inflation, tariffs, foreign currency fluctuations, and the outcome of ongoing litigation.
Investor Verification Checklist
- CEO Succession Plan: Verify the timeline and progress of the CEO search committee following James C. Clemmer's announced retirement.
- Restructuring Execution: Monitor the completion of the manufacturing footprint optimization and the associated cash outflows versus the estimated $33.4M–$38.4M total cost.
- Med Tech Growth Sustainability: Assess the durability of the 13%+ growth in the Med Tech segment, specifically regarding Auryon and NanoKnife adoption rates.
- Product Liability Exposure: Review updates on the 268 pending port product liability claims and potential reserve adjustments.
- Cash Burn Rate: Evaluate the trend in operating cash flow usage ($11.3M for six months) against the $41.6M cash balance to determine runway without additional financing.